NASDAQ:REPL Replimune Group Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Replimune Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.09 +1.51 (+7.00 %) (As of 09/29/2020 12:37 PM ET) Add Compare Share Today's Range$21.59Now: $23.09▼$23.0950-Day Range$20.64MA: $23.81▼$27.0052-Week Range$8.58Now: $23.09▼$27.69Volume3,429 shsAverage Volume159,815 shsMarket Capitalization$930.25 millionP/E RatioN/ADividend YieldN/ABeta3.2 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.07, Replimune Group has a forecasted upside of 23.6% from its current price of $21.90.Amount of Analyst CoverageReplimune Group has only been the subject of 3 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesReplimune Group has received 118 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReplimune Group has received 138 “underperform” votes. (Add your “underperform” vote.)Community SentimentReplimune Group has received 53.91% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote “Outperform” if you believe REPL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,243,418.00 in company stock.Percentage Held by Insiders50.90% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.86% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to decrease in the coming year, from ($1.78) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -13.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -13.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL Previous Symbol CUSIPN/A CIKN/A Webwww.replimune.com Phone781-222-9600Debt Debt-to-Equity Ratio0.14 Current Ratio22.54 Quick Ratio22.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.01 per share Price / Book4.61Profitability EPS (Most Recent Fiscal Year)($1.54) Net Income$-52,630,000.00 Net MarginsN/A Return on Equity-31.09% Return on Assets-25.11%Miscellaneous Employees62 Outstanding Shares40,288,000Market Cap$930.25 million Next Earnings Date11/9/2020 (Estimated) OptionableNot Optionable $23.09 +1.51 (+7.00 %) (As of 09/29/2020 12:37 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive REPL News and Ratings via Email Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Replimune Group (NASDAQ:REPL) Frequently Asked Questions How has Replimune Group's stock price been impacted by COVID-19? Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REPL stock has increased by 93.5% and is now trading at $23.09. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Replimune Group? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Replimune Group. When is Replimune Group's next earnings date? Replimune Group is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020. View our earnings forecast for Replimune Group. How were Replimune Group's earnings last quarter? Replimune Group Inc (NASDAQ:REPL) released its quarterly earnings results on Friday, August, 7th. The company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44). View Replimune Group's earnings history. What price target have analysts set for REPL? 7 brokerages have issued twelve-month price objectives for Replimune Group's shares. Their forecasts range from $12.50 to $40.00. On average, they anticipate Replimune Group's stock price to reach $27.07 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price. View analysts' price targets for Replimune Group. Are investors shorting Replimune Group? Replimune Group saw a increase in short interest in September. As of September 15th, there was short interest totaling 687,300 shares, an increase of 21.5% from the August 31st total of 565,600 shares. Based on an average daily volume of 213,500 shares, the days-to-cover ratio is presently 3.2 days. Approximately 3.5% of the shares of the stock are sold short. View Replimune Group's Short Interest. Who are some of Replimune Group's key competitors? Some companies that are related to Replimune Group include Relay Therapeutics (RLAY), Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), Kodiak Sciences (KOD), Sorrento Therapeutics (SRNE), Mesoblast (MESO), Revolution Medicines (RVMD), Forma Therapeutics (FMTX), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), NanoString Technologies (NSTG), Allovir (ALVR) and Cortexyme (CRTX). View all competitors. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). Who are Replimune Group's key executives? Replimune Group's management team includes the following people: Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)Dr. Robert Coffin, Pres, CEO & Director (Age 54)Dr. Colin Love, Chief Operating Officer (Age 61)Dr. Pamela Esposito, Chief Bus. Officer (Age 45)Stephen Gorgol, Chief Accounting Officer When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." How do I buy shares of Replimune Group? Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $23.09. How big of a company is Replimune Group? Replimune Group has a market capitalization of $930.25 million. The company earns $-52,630,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Replimune Group employs 62 workers across the globe. What is Replimune Group's official website? The official website for Replimune Group is www.replimune.com. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
